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ABSTRACT
P53 is a key regulator of many cellular processes and is negatively regulated by the 
human homolog of murine double minute-2 (MDM2) E3 ubiquitin ligase. Single nucleotide 
polymorphisms (SNPs) of either gene alone, and in combination, are linked to cancer 
susceptibility, disease progression, and therapy response. We analyzed the interaction 
of TP53 R72P and MDM2 SNP309 SNPs in relationship to outcome in patients with 
myelodysplastic syndromes (MDS). Sanger sequencing was performed on DNA isolated 
from 208 MDS cases. Utilizing a novel functional SNP scoring system ranging from +2 
to −2 based on predicted p53 activity, we found statistically significant differences in 
overall survival (OS) (p = 0.02) and progression-free survival (PFS) (p = 0.02) in non-
del(5q) MDS patients with low functional scores. In univariate analysis, only IPSS and 
the functional SNP score predicted OS and PFS in non-del(5q) patients. In multivariate 
analysis, the functional SNP score was independent of IPSS for OS and PFS. These data 
underscore the importance of TP53 R72P and MDM2 SNP309 SNPs in MDS, and provide 
a novel scoring system independent of IPSS that is predictive for disease outcome.
INTRODUCTION
The myelodysplastic syndromes (MDS) share 
phenotypic features of dysplastic and ineffective 
hematopoiesis accompanied by remarkable hematologic, 
genetic and clinical heterogeneity. Although clinical 
scoring systems provide tools for prognostic 
discrimination, they overlook biologic features potentially 
relevant to disease behavior [1]. The tumor suppressor 
gene, TP53, is a key regulator of many cellular processes, 
and is a key driver of hematologic features of disease 
in MDS. P53 is particularly important in patients with 
MDS harboring an interstitial deletion of chromosome 
5q [del(5q)], where RPS14 haploinsufficiency results in 
ribosomal stress liberating free ribosomal proteins that 
bind to, and trigger degradation of the primary negative 
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regulator of p53, the human homologue of murine double 
minute-2 (MDM2) [2–4]. TP53 mutations are found in the 
vast majority of solid tumors [5]. However, in MDS, TP53 
mutations are demonstrable in approximately 10% of all 
cases, 20% of del(5q) cases, and more than 70% of cases 
with a complex karyotype [6, 7]. Mutations involving the 
DNA binding domain (DBD) of TP53 carry a particularly 
poor prognosis [7]. Upregulation of MDM2 has also been 
observed in many malignancies including up to 10% of 
MDS cases [8]. Recently, we demonstrated the importance 
of MDM2 in the activity of lenalidomide, whereby 
inhibition of the E3 ubiquitin ligase activity of MDM2 
resulted in stabilization of the protein and corresponding 
degradation of p53 in del(5q) MDS, illustrating the critical 
role of these proteins in MDS disease biology, progression 
and therapeutic response [4].
Single nucleotide polymorphisms (SNPs) of both 
TP53 and MDM2 have been linked to earlier cancer 
onset, greater cancer risk, and response to therapy [9–13]. 
The non-synonymous, SNP of TP53, R72P at codon 72, 
resides in exon 4 outside the DBD, and has been linked 
to cancer susceptibility in patients with solid tumors 
[14, 15]. Among hematologic malignancies, associations 
between the R72P SNP and clinical features have been 
conflicting [9, 10, 16, 17]. A G- to C-allele substitution 
results in an arginine to proline amino acid change, 
predictably affecting the structure of the SH-3 domain, 
and the functionality of the protein [18, 19]. For example, 
the C-allele has been shown to have diminished apoptotic 
potential in vitro [19]. In a recent study of more than 700 
MDS patients, we found no overall association of R72P 
alone with disease outcome in MDS; however, there was a 
trend towards inferior survival with the G-allele in patients 
with del(5q) MDS, and a significant association of this 
allele with telomeric deletions involving 5q34 [17]. In 
non-del(5q) MDS, C-allele homozygozity was associated 
with non-significantly inferior survival demonstrating 
the differential impact of the p53 SNP in cytogenetically 
distinct MDS populations [17].
A well-studied SNP in MDM2, SNP309, has also 
been linked to increased cancer risk [12, 13]. Here, 
substitution of the ancestral T-allele with a G-allele 
introduces an additional Sp1 transcription factor binding 
site in the MDM2 promoter. This leads to increased 
MDM2 expression, and decreases in the cellular levels 
of p53. In hematological malignancies, the MDM2 
SNP309 G-allele is associated with increased risk for 
acute myeloid leukemia (AML) and chronic myelogenous 
leukemia (CML) [20, 21]. Additionally, there have been 
a number of studies analyzing the effects of R72P and 
SNP309 interactions in solid tumors, demonstrating 
combined effects on clinical features and prognosis 
of disease [22–24]. Previous reports of these SNP 
combinations in MDS did not distinguish between del(5q) 
and non-del(5q) MDS patients [16].
In this study, we examine the effect of the 
combination of TP53 R72P and MDM2 SNP309 on 
clinical features of del(5q) and non-del(5q) MDS, and 
find significant differences in survival based on genotypic 
interaction.
RESULTS
Patient demographics
We analyzed 208 MDS patients [95 non-del(5q), 
102 del(5q), and 11 with unknown cytogenetics]. The 
median OS of our cohort was 52.9 months [40.3–65.7]. 
Median age at diagnosis was 71 [range 27–89]. The male 
to female ratio was 111/97. The distribution of IPSS 
category, cytogenetic risk group, WHO subclassification, 
and genotype frequencies are summarized in Table 1. 
Patient cytogenetics are listed in Supplemental Table 1.
Functional SNP scoring system predicts outcome
In a recent study, we found there was no significant 
association of R72P genotype alone with survival in either 
del(5q) or non-del(5q) MDS [17]. Here, analysis of the 
MDM2 SNP309 genotype alone also demonstrated no 
influence on either OS [p = 0.419, non-del(5q); p = 0.123, 
del(5q)] or PFS [p = 0.193, non-del(5q); p = 0.612, 
del(5q)]. In order to analyze the interactions of R72P and 
SNP309 encoded proteins, we created a SNP functional 
score based upon predicted p53 activity. As the G-allele in 
SNP309 increases MDM2 expression, thereby enhancing 
p53 degradation, and the R72P C-allele has diminished 
apoptotic potential [19], we weighted the MDM2/TP53 
GG/CC genotype combination lowest with a score 
of − 2. Conversely, the TT/GG genotype combination 
had the greatest score at +2. The double heterozygotes 
were assigned a score of 0, and all intermediate genotype 
combinations are summarized in Table 2. Patients were 
then stratified into either high p53 functional score 
(equal to or greater than 0) or low p53 functional scoring 
groups (below 0). We did not discern any significant 
associations with age, sex, race, WHO subclassification, 
cytogenetic risk group, IPSS, or IPSS-R in either del(5q) 
or non-del(5q) MDS, or within the entire patient cohort. 
These analyses and their corresponding p-values are 
summarized in Table 3. We then applied the functional 
SNP scoring system to assess relationship to OS and 
found there was no significant association among the 
combined MDS cases (p = 0.54) with similar results for 
PFS (p = 0.66). Median OS was 53.9 months (19.6–88.3) 
and 54.0 months (40.2–67.8) in low and high scorers, 
respectively. Median PFS was 50.0 months (20.2–79.8) 
and 46.9 months (36.8–57.0) in low and high scorers, 
respectively. Given the importance of p53 in the 
physiopathology of del(5q) MDS as a result of ribosomal 
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Table 2: TP53/MDM2 scoring system
MDM2 SNP309/TP53 R72P Points
GG/CC − 2
TT/CC − 1
GG/GC or TG/CC − 0.5
TG/CG 0
TT/GC or TG/GG 0.5
GG/GG 1
TT/GG 2
Sub-groups Points
Score Low < 0
Score High ≥ 0
Table 1: Patient demographics
n = 208
Median age (range) 71 (27–89)
Sex ratio M/F 111/97
Race
Caucasian
Non Caucasian
189 (91%)
19 (9%)
WHO classification (%)
MDS with Isolated 5q
Other1
RAEB-1
RAEB-2
20 (10%)
83 (35%)
30 (14%)
11 (5%)
IPSS cytogenetic risk
Good
Intermediate
Poor
137 (66%)
24 (12%)
31 (15%)
IPSS
Low
Intermediate-1
Intermediate-2
High
105 (50%)
72 (35%)
25 (12%)
4 (2%)
IPSS-R
Very Low
Low
Intermediate
High
Very High
85 (51%)
20 (35%)
47 (12%)
14 (7%)
15 (7%)
n (%)
1Other (RA, RARS, RCMD, RCMD-RS)
Missing data was excluded from table
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stress, the greater incidence of TP53 mutations in this 
MDS subtype, as well as our previous study of R72P SNP 
alone, it was imperative that we analyze del(5q) MDS 
and non-del(5q) MDS separately. We found a statistically 
significant difference in OS based on the functional SNP 
score in non-del(5q) MDS patients (p = 0.02). Median OS 
in high scorers was 61.0 months (37.7–84.4) compared to 
a median OS of 23.0 months (9.9–36.1) in low scorers 
(Figure 1). We then analyzed PFS and found a statistically 
significant increase in PFS in those patients with a high 
functional SNP score compared to those with the lower 
SNP score [p = 0.02, median PFS was 53.0 months 
(33.0–73.0) for high and 23.0 months (13.7–32.3) for 
low] (Figure 1). In del(5q) MDS patients, we did not 
observe significant differences in OS or PFS according 
to functional SNP score. Median OS was 77.9 months 
(45.4–110.5) and 47.5 months (29.0–66.1) in low and high 
score groups, respectively (p = 0.27), while median PFS 
Table 3: Correlations between clinical parameters and p53 functional SNP scoring system
Non-del(5q) MDS Del(5q) MDS patients
Functional SNP Scoring System Low n = 20 High n = 75 Low n = 26 High n = 76
Median age (range) 70 (38–85) 71 (27–89)p = 0.89 69 (45–82)
72 (27–89)
p = 0.90
Sex ratio M/F 15/5 52/23p = 0.62 7/19
32/44
p = 0.17
Race
Caucasian
Non Caucasian
20(100%)
0
68 (91%)
8(9%)
p = 0.92
24 (92%)
2 (8%)
68 (86%)
8 (14%)
p = 0.87
WHO classification
MDS with Isolated 5q
Other1
RAEB-1
RAEB-2
0
13 (65%)
4 (20%)
3 (15%)
0
64 (85%)
6 (8%)
3 (4%)
p = 0.06
9 (35%)
10 (38%)
4 (15%)
2 (8%)
25 (32%)
29 (36%)
15 (18%)
6 (8%)
p = 0.95
IPSS cytogenetic risks
Good
Intermediate
Poor
17 (85%)
1 (5%)
2 (10%)
56 (75%)
14 (19%)
4 (5%)
p = 0.27
14 (54%)
2 (8%)
6 (23%)
42 (55%)
6 (8%)
18 (24%)
p = 0.99
IPSS
Low
Intermediate-1
Intermediate-2
High
7 (35%)
10 (50%)
2 (10%)
1 (5%)
39 (52%)
30 (40%)
5 (7%)
1 (1%)
p = 0.46
13 (50%)
9 (35%)
3 (11%)
1 (4%)
40 (53%)
21 (28%)
14 (18%)
1 (1%)
p = 0.68
IPSS-R
Very Low
Low
Intermediate
High
Very High
6 (30%)
1 (5%)
6 (30%)
4 (20%)
3 (15%
19 (24%)
13 (16%)
32 (40%)
10 (12%)
5 (6%)
p = 0.33
18 (69%)
1 (4%)
1 (4%)
0
2 (8%)
41 (54%)
4 (5%)
7 (9%)
0 (0%)
5 (7%)
p = 0.73
P53 R72P SNP
CC
CG
GG
10 (50%)
10 (50%)
0
0
39 (52%)
36 (48%)
21 (81%)
5 (19%)
0
0
34 (45%)
42 (55%)
MDM2 SNP309
GG
TT
TG
13 (65%)
5 (25%)
2 (10%)
8 (11%)
33 (44%)
34 (45%)
8 (31%)
9 (35%)
9 (35%)
4 (5%)
29 (38%)
43 (57%)
n (%)
1Other (RA, RARS, RCMD, RCMD-RS)
Missing data was excluded from table
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was 77.9 months (45.4–110.5) vs. 41.9 months (28.0–66.1) 
in low and high score cohorts, respectively (p = 0.19).
Univariate and mutlivariate analysis
We then analyzed potential variables impacting OS 
and PFS in non-del(5q) MDS by univariate analysis. We 
found that age at diagnosis, gender, and cytogenetic risk 
group did not predict OS. IPSS had a significant impact on 
survival [Hazard Ratio (HR) 2.36 (95%, CI, 1.45–3.85), 
p = 0.001], and we approached a significant impact for 
both WHO diagnostic category and IPSS-R [HR 1.27 
(95%, CI, 0.99–1.64), p = 0.07; and HR 1.31 (95%, CI, 
0.95–1.79), p = 0.09, respectively]. Furthermore, we 
found discrimination by the p53 functional SNP score also 
significantly impacted OS with an HR of 0.42 [95% CI, 
0.21–0.85, p = 0.02]. Similar results were found for PFS 
in univariate analysis in which WHO diagnostic category 
had an HR of 1.28 [95%, CI 1.01–1.63, p = 0.04] while 
IPSS had an HR of 2.50 [95%, CI 1.56–4.00, p < 0.0001] 
and the p53 functional score had an HR 0.46 [95%, 
CI 0.23–0.89, p = 0.02] (Table 4). In our cohort, we did 
not reach statistical significance with IPSS-R in univariate 
analysis for PFS (p = 0.13). In the multivariate analysis, 
the p53 SNP functional score significantly impacted 
OS independent of IPSS. HR for IPSS was 2.89 [95% CI, 
1.77–4.73, p < 0.0001] and for the p53 SNP functional 
score HR was 0.25 [95% CI, 0.11–0.58, p = 0.001] 
(Table 5). The significance of the p53 functional score on 
OS was also independent of IPSS-R. The functional score 
was similarly independent of IPSS for PFS, HR for IPSS 
was 2.84 [95% CI, 1.78–4.53, p < 0.0001] and for the p53 
SNP functional score, HR was 0.33 [95% CI, 0.15–0.74, 
p = 0.006] (Table 5).
DISCUSSION
In this study, we have shown that the predicted 
activity of p53 has prognostic importance in non-del(5q) 
MDS. Using a scoring system based on the predicted 
function of the encoded p53 protein using TP53 R72P 
and MDM2 SNP309, we found that those patients with 
a high p53 SNP activity score had significantly longer 
OS and PFS compared to those patients with a low p53 
SNP functional score. In contrast, we did not find a 
significant impact of the p53 SNP score on outcome in 
patients with del(5q) MDS. However, it is possible that if 
those patients harboring a TP53 mutation were excluded, 
the score may have greater prognostic significance. We 
hypothesize that TP53 mutations will have a negative 
effect on our scoring system due to inefficient clearing 
of mutant p53 by MDM2 [25]. Unfortunately, TP53 
mutation status was not available for the patients in 
our data set. Analysis of this scoring system in del(5q) 
patients, in particular comparing TP53 mutations vs 
those without, may delineate whether this scoring system 
should be utilized in either MDS subtype, or, should be 
restricted to non-del(5q) patients only. As was described 
by Bejar et al., [26] addition of molecular entities such as 
mutations should be included in current scoring systems. 
The authors demonstrate the negative impact of specific 
somatic mutations, and that presence or absence of such 
mutations, prognostically differentiates individuals with 
Figure 1: Kaplan-Meier plots of survival based upon SNP functional score. A. OS and B. PFS of low scoring (score of less 
than 0) and high scoring patient cohorts (score equal to or greater than 0) based on weighted R72P and SNP309 p53 activity score.
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similar IPSS or IPSS-R scores; and, that those individuals 
with mutations should be placed into the next higher risk 
category. We similarly suggest here, that germline SNPs 
may also provide refined prognostication, and therefore, 
need to be explored further to determine whether they 
should also be considered. Sequencing of these SNPs 
by the Sanger method or by inclusion in current next-
generation sequencing panels in larger validation cohorts 
should be used to determine whether patients harboring a 
low functional SNP score should similarly be upgraded 
to the next risk category as suggested with mutation 
status. These data also confirm the importance of p53 
activity in these heterogeneous disorders. The association 
of p53 activity with respect to MDS features such as 
cytopenias, bone marrow blast count, cytogenetics and 
even clonal hematopoiesis should be explored. Potential 
methods to explore p53 activity include IHC or p53 
nuclear localization. Although p53 IHC immunostaining 
Table 5: Multivariate analysis for OS and PFS
Multivariate analysis for OS HR (CI-95%) p-value
IPSS (Low/Int/High) 2.89 [1.77–4.73] p < 0.0001
TP53/MDM2 SNP Scoring System (Low/High) 0.25 [0.11–0.58] p = 0.001
Multivariate analysis for OS HR (CI-95%) p-value
IPSS-R (VL/L/I/H/VH) 1.29 [0.94–1.78] p = 0.12
TP53/MDM2 SNP Scoring System (Low/High) 0.41 [0.20–0.84] p = 0.01
Multivariate analysis for PFS HR (CI-95%) p-value
IPSS (Low/Int/High) 2.84 [1.78–4.53] p < 0.0001
TP53/MDM2 SNP Scoring System (Low/High) 0.33 [0.15–0.74] p = 0.006
Table 4: Univariate analysis for OS and PFS
Univariate analysis for OS HR (CI-95%) p-value
Age 1.01 [0.98–1.04] p = 0.62
Sex 0.89 [0.45–1.76] p = 0.74
WHO classification (Others/RAEB1/RAEB2) 1.27 [0.99–1.64] p = 0.07
Cytogenetic risk (Low/Int/High) 1.35 [0.77–2.36] p = 0.29
IPSS (Low/Int/High) 2.36 [1.45–3.85] p = 0.001
IPSS-R (VL/L/I/H/VH) 1.31 [0.95–1.79] p = 0.09
TP53/MDM2 SNP Scoring System (Low/High) 0.42 [0.21–0.85] p = 0.02
Univariate analysis for PFS HR (CI-95%)> p-value
Age 1.01 [0.98–1.04] p = 0.52
Sex 0.86 [0.45–1.66] p = 0.66
WHO classification (Others/RAEB1/RAEB2) 1.28 [1.01–1.63] p = 0.04
Cytogenetic risk (Low/Int/High) 1.49 [0.88–2.53] p = 0.14
IPSS (Low/Int/High) 2.50 [1.56–4.00] p < 0.0001
IPSS-R (VL/L/I/H/VH) 1.25 [0.94–1.67] p = 0.13
TP53/MDM2 SNP Scoring System (Low/High) 0.46 [0.23–0.89] p = 0.02
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has been suggested as a prognostic indicator, particularly 
with respect to being a surrogate marker for mutant 
TP53, [27] the utility of p53 IHC to predict p53 activity 
is not feasible. As p53 activity may be influenced by 
environmental factors, previous therapies, or previous 
conditions, IHC or subcellular compartmentalization at 
the time of diagnosis cannot provide an accurate measure 
of basal p53 activity. However, the presence of germline 
polymorphisms that can predict basal p53 functionality 
and that occur independent of environmental factors, may 
have prognostic utility.
These data underscore for the first time the 
importance of these SNPs in non-del(5q) MDS. Given the 
varied natural history of disease in MDS, identification 
of a genetic signature that complements IPSS to predict 
outcome has significant importance for treatment 
selection. The relationship of the TP53 SNP score to 
prognostically important somatic gene mutations warrants 
investigation in future studies. Investigations have shown 
that TP53 gene mutation is associated with lower overall 
response to lenalidomide and inferior overall survival in 
IPSS higher risk MDS patients treated with azacitidine 
[7, 28]. A similar analysis of our TP53/MDM2 scoring 
system in relation to treatment outcome may offer further 
prognostic discrimination and merits investigation. Based 
on these data, the interaction of TP53 R72P and MDM2 
SNP309 should be validated in a larger cohort of patients.
MATERIALS AND METHODS
Patients and DNA isolation
DNA was isolated from bone marrow mononuclear 
cells obtained from 208 MDS cases [del(5q), n = 102; 
non-del(5q), n = 95; unknown, n = 11] who provided 
written consent on protocols approved by the University 
of South Florida (USF) Institute Review Board (IRB), or 
equivalent, institutional approved protocols as previously 
described. [17] Median follow up of patients was 
30 months.
Clinical characteristics
World Health Organization (WHO) diagnostic 
category, and cytogenetic and International Prognostic 
Scoring System (IPSS) risk score was defined as 
previously described. [17] All cases, which included more 
than 90% Caucasians, were analyzed regardless of race.
Sanger sequencing
Sequencing of TP53 R72P was performed as 
previously described. [17] MDM2 SNP309 was similarly 
sequenced with the primers forward 5′-CGG GAG TTC 
AGG GTA AAG GT-3′ and reverse 5′-AGC AAG TCG 
GTG CTT ACC TGG-3′ using an amplification protocol of 
94°C for 2 minutes then 25 cycles at 94°C for 30 seconds, 
62°C for 30 seconds and 72°C for 30 seconds, followed by 
5 minutes final extension at 72°C.
Statistical analysis
Patient characteristics and TP53/MDM2 scoring 
group associations were performed using the Chi-squared 
test for binary variables and the Mann-Whitney test for 
continuous variables. OS and PFS were estimated using 
the Kaplan-Meier method and compared with the log-rank 
test. Overall survival (OS) was defined as the interval from 
diagnosis to the date of death. Progression-free survival 
(PFS) was defined as the interval from diagnosis to the 
date of AML progression. Multivariate analysis was 
performed using the Cox regression model. P-values 
below 0.05 were considered statistically significant. 
Statistical analyses were performed using SPSS software 
v22 (IBM, Armonk, NY).
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